Cargando…
Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review
Immune checkpoint inhibitors (ICIs) are increasingly being used in the treatment of advanced human malignancies. ICIs-related adverse events, including pancreatitis and diabetes, have been individually characterized in the literature. The co-occurrence of ICIs-related pancreatitis with diabetes is r...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569069/ https://www.ncbi.nlm.nih.gov/pubmed/37841238 http://dx.doi.org/10.3389/fimmu.2023.1243773 |
_version_ | 1785119488473038848 |
---|---|
author | Fang, Wei Gao, Yang Shi, Xiaoyan Zhang, Xiaoran Zhou, Shan Zhu, Hongxia Yan, Wei Wang, Huanping |
author_facet | Fang, Wei Gao, Yang Shi, Xiaoyan Zhang, Xiaoran Zhou, Shan Zhu, Hongxia Yan, Wei Wang, Huanping |
author_sort | Fang, Wei |
collection | PubMed |
description | Immune checkpoint inhibitors (ICIs) are increasingly being used in the treatment of advanced human malignancies. ICIs-related adverse events, including pancreatitis and diabetes, have been individually characterized in the literature. The co-occurrence of ICIs-related pancreatitis with diabetes is rare and easily overlooked, but it is often severe or fatal. We present a patient with renal tumor resection who was treated with injection of the PD-L1 inhibitor toripalimab and eventually developed acute pancreatitis and fulminant type 1 diabetes mellitus. In addition, we conducted a literature review of ICIs-related pancreatitis with diabetes. The case in our report presented with paroxysmal abdominal pain and loss of appetite. Intravenous fluids and insulin infusion improved the patient’s pancreatitis and explosive hyperglycemia. This article suggests that ICIs can affect endocrine and exocrine functions of the pancreas, while providing information and new perspectives for the diagnosis and treatment of this challenging rare disease, helping inspire clinicians for the early identification and effective management of similar cases. |
format | Online Article Text |
id | pubmed-10569069 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105690692023-10-13 Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review Fang, Wei Gao, Yang Shi, Xiaoyan Zhang, Xiaoran Zhou, Shan Zhu, Hongxia Yan, Wei Wang, Huanping Front Immunol Immunology Immune checkpoint inhibitors (ICIs) are increasingly being used in the treatment of advanced human malignancies. ICIs-related adverse events, including pancreatitis and diabetes, have been individually characterized in the literature. The co-occurrence of ICIs-related pancreatitis with diabetes is rare and easily overlooked, but it is often severe or fatal. We present a patient with renal tumor resection who was treated with injection of the PD-L1 inhibitor toripalimab and eventually developed acute pancreatitis and fulminant type 1 diabetes mellitus. In addition, we conducted a literature review of ICIs-related pancreatitis with diabetes. The case in our report presented with paroxysmal abdominal pain and loss of appetite. Intravenous fluids and insulin infusion improved the patient’s pancreatitis and explosive hyperglycemia. This article suggests that ICIs can affect endocrine and exocrine functions of the pancreas, while providing information and new perspectives for the diagnosis and treatment of this challenging rare disease, helping inspire clinicians for the early identification and effective management of similar cases. Frontiers Media S.A. 2023-09-28 /pmc/articles/PMC10569069/ /pubmed/37841238 http://dx.doi.org/10.3389/fimmu.2023.1243773 Text en Copyright © 2023 Fang, Gao, Shi, Zhang, Zhou, Zhu, Yan and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Fang, Wei Gao, Yang Shi, Xiaoyan Zhang, Xiaoran Zhou, Shan Zhu, Hongxia Yan, Wei Wang, Huanping Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review |
title | Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review |
title_full | Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review |
title_fullStr | Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review |
title_full_unstemmed | Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review |
title_short | Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review |
title_sort | immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569069/ https://www.ncbi.nlm.nih.gov/pubmed/37841238 http://dx.doi.org/10.3389/fimmu.2023.1243773 |
work_keys_str_mv | AT fangwei immunecheckpointinhibitorsrelatedpancreatitiswithfulminanttype1diabetesmellituscasereportandliteraturereview AT gaoyang immunecheckpointinhibitorsrelatedpancreatitiswithfulminanttype1diabetesmellituscasereportandliteraturereview AT shixiaoyan immunecheckpointinhibitorsrelatedpancreatitiswithfulminanttype1diabetesmellituscasereportandliteraturereview AT zhangxiaoran immunecheckpointinhibitorsrelatedpancreatitiswithfulminanttype1diabetesmellituscasereportandliteraturereview AT zhoushan immunecheckpointinhibitorsrelatedpancreatitiswithfulminanttype1diabetesmellituscasereportandliteraturereview AT zhuhongxia immunecheckpointinhibitorsrelatedpancreatitiswithfulminanttype1diabetesmellituscasereportandliteraturereview AT yanwei immunecheckpointinhibitorsrelatedpancreatitiswithfulminanttype1diabetesmellituscasereportandliteraturereview AT wanghuanping immunecheckpointinhibitorsrelatedpancreatitiswithfulminanttype1diabetesmellituscasereportandliteraturereview |